FIGURE 3 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Year: 2023
Type: other
Abstract: Anti-ORF1p IgG response in serum samples from patients with five cancer types. A, Selection of cancers for analysis in anti-ORF1p immunoassay. Sector sizes are proportional to the incidence of these cancers in the United States in 2021 (https://seer.cancer.gov/statfacts/). Color code indicates a 5-year survival. “S” stands for the existence of approved cancer screening protocols. B, Detection of anti-ORF1p IgG titers in serum samples of patients with the indicated cancer types of all stages. Sample size: ovary (N = 979), esophagus (N = 377), lung (N = 907), pancreas (N = 124), liver (N = 217) cancers and healthy (N = 352). C, The same as panel B; only samples from patients with cancer stages 1 and 2 are shown. Sample size: ovary (N = 193), esophagus (N = 79), lung (N = 90), pancreas (N = 40), and liver (N = 67) cancers and healthy (N = 352). The gray areas in B and C mark samples below the anti-ORF1p IgG titer threshold of 450. Statistics were calculated by Dunn multiple comparison test with adjusted P value for anti-ORF1p IgG titers. All P value less than 0.05 is considered significant. D, Anti-ORF1p immunoassay threshold determination. E, Spearman r correlation analysis of anti-ORF1p IgG titers and age among healthy individuals (20–89 years of age) or patients with cancer (18–95 years of age).
Authors: Alexandra V. Vylegzhanina, Ivan A. Bespalov, Ksenia A. Novototskaya-Vlasova, Brandon M. Hall, Anatoli S. Gleiberman, Han Yu, Olga V. Leontieva, Katerina I. Leonova, Oleg V. Kurnasov, Andrei L. Osterman, Grace K. Dy, Alexey A. Komissarov, Elena Vasilieva, Jeff Gehlhausen, Akiko Iwasaki, Christine B. Ambrosone, Takemasa Tsuji, Junko Matsuzaki, Kunle Odunsi, Ekaterina L. Andrianova, Andrei V. Gudkov
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4388490270